Liver transplant breakthrough: could this end lifelong drug dependency?
NCT ID NCT07634562
First seen Jun 11, 2026 · Last updated Jun 11, 2026
Summary
This early-stage study tests whether a combination of total lymphoid irradiation and anti-thymocyte globulin, given after a standard liver transplant, can train the body to accept the new organ without needing lifelong immune-suppressing drugs. Twelve adult liver transplant recipients will be enrolled at Stanford University. The goal is to safely reduce and eventually stop all anti-rejection medication within two years while keeping the liver healthy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER FAILURE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Stanford University
Stanford, California, 94305, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.